HIGHLIGHTS
- who: Christoph Hoeller from the Department of Dermatology, Medical University Vienna, Waehringer Guertel, Vienna, Austria have published the paper: Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma, in the Journal: (JOURNAL)
- what: In this trial, significantly fewer grade 3-5 adverse events were reported in patients receiving GM-CSF in combination with ipilimumab than in those receiving ipilimumab alone (44.9 vs. 58.3 %; P=0.04); however, there were high numbers of deaths in both treatment groups. Since the completion of this systematic review, a double . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.